{"schema_version":"secwatch.filing_event.v1","accession":"0001662579-23-000040","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.055406+00:00","generated_at":"2026-06-19T02:49:33.887934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"C4 Therapeutics Reports Q4 and Full Year 2022 Financial Results with Net Loss of $128.2M and Cash Runway to End of 2024","bullets":["Revenue for 2022 was $31.1M, down from $45.8M in 2021, primarily due to one-time recognition in prior year from Roche agreement termination.","Net loss for 2022 was $128.2M ($2.62 per share) compared to $83.9M ($1.82 per share) in 2021, driven by increased R&D and G&A expenses.","Cash, cash equivalents and marketable securities totaled $337.1M as of Dec 31, 2022, expected to fund operations through end of 2024.","Phase 1 dose escalation data for CFT7455 (multiple myeloma) and CFT8634 (synovial sarcoma) expected in second half of 2023.","IND submission for CFT8919 (EGFR L858R degrader) on track for first half of 2023; CFT1946 Phase 1/2 trial dosing first patient in January 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001662579-23-000040","json":"https://secwatch.observer/filing/0001662579-23-000040.json","markdown":"https://secwatch.observer/filing/0001662579-23-000040.md","text":"https://secwatch.observer/filing/0001662579-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000040/0001662579-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000166257923000040/cccc-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:49:33.887934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}